LUMO
Lumos Pharma, Inc. [LUMO] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
LUMO Stock Summary
In the News
LUMO Financial details
Company Rating
-
Market Cap
21.4M
Income
-33.35M
Revenue
2.05M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
33
Optionable
No
Shortable
Yes
Earnings
01 May 2024
P/E
-0.77
Forward P/E
-
PEG
-0.71
P/S
13.94
P/B
0.69
P/C
-
P/FCF
-0.81
Quick Ratio
7.01
Current Ratio
7.76
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-4.11
EPS next Y
-
EPS next Q
-
EPS this Y
12.67%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-57.38%
Revenue last 5Y
16.99%
Revenue Q/Q
11700%
EPS Q/Q
12.5%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-66%
ROE
-66%
ROC
-0.85%
Gross Margin
100%
Oper. Margin
-2041%
Profit Margin
-1817%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.41-4.55
52W High
+8.5%
52W Low
+117%
RSI
58.45
Rel Volume
-
Avg Volume
21.01K
Volume
Perf Week
0.46%
Perf Month
-2.25%
Perf Quarter
-
Perf Half Y
16.35%
-
-
-
-
Beta
0.35
-
-
Volatility
0%, 0.03%
Prev Close
0%
Price
4.34
Change
0%
Company Profile
- Volume Average 21.01K
- Market Capitalization 21.4M
- Employee 33
- CEO Mr. Richard J. Hawkins
- Headquarters Austin,TX,US
- IPO Date 2011-11-11
-
Website
https://www.lumos-pharma.com 
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
